BioSpace News Archive

Johnson & Johnson Medical Devices Companies* today announced Ethicon** has launched a new global registry to collect and analyze real-world data on patients with soft tissue liver lesions ablated with the company’s NEUWAVE Microwave Ablation System.

The following letter was sent by CEL-SCI Corporation (NYSE American: CVM) to its shareholders for the upcoming annual meeting

Ciming Boao International Hospital and Fertility Center, a state-of-the-art 5,000sq meter facility has begun trial operations.

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that it has entered into an agreement with funds managed by Oberland Capital Management, LLC (“Oberland Capital”) for up to $135.7 million in exchange for selling rights to a portion of royalty revenues on worldwide net sales of Erivedge.

Alcyone Lifesciences, Inc., a leader in transforming Disease Modifying Therapies for the Central Nervous System (CNS) and Oncology through its Advanced Precision Delivery Platforms, announced a presentation on its advanced precision therapy delivery platform for Antisense Oligonucleotide (ASO) and Gene Therapy at the 2019 Oligonucleotide Discovery and Delivery Conference.

Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma” or the “Company”) today announced that data from the Company’s Phase 2 clinical trial of ampreloxetine (TD-9855) have been selected for an oral presentation at the 32nd European Neurology Congress.

The California Mesothelioma Victims Center has a background in the waterworks or water district workplaces, as well as almost any group in the nation, and they are committed to seeing to it that a waterworks worker with mesothelioma or asbestos exposure lung cancer receives the very best possible financial compensation settlement results.

Vireo Health International, Inc. announced the acquisition of four entities which together manage the vertically-integrated medical cannabis business of license-holder Arizona Natural Remedies.

Data from a Phase 2 study in congenital hyperinsulinism (CHI) shared at ENDO 2019 and a budget impact model presented at AMCP reinforce the utility of Xeris’ ready-to-use, liquid-stable glucagon